Accelerated RNA detection using tandem CRISPR nucleases

Direct, amplification-free detection of RNA has the potential to transform molecular diagnostics by enabling simple on-site analysis of human or environmental samples. CRISPR-Cas nucleases offer programmable RNA-guided recognition of RNA that triggers cleavage and release of a fluorescent reporter molecule1,2, but long reaction times hamper sensitivity and speed when applied to point-of-care testing. Here we show that unrelated CRISPR nucleases can be deployed in tandem to provide both direct RNA sensing and rapid signal generation, thus enabling robust detection of ~30 RNA copies/microliter in 20 minutes. Combining RNA-guided Cas13 and Csm6 with a chemically stabilized activator creates a one-step assay that detected SARS-CoV-2 RNA from nasopharyngeal samples with PCR-derived Ct values up to 29 in microfluidic chips, using a compact imaging system. This Fast Integrated Nuclease Detection In Tandem (FIND-IT) approach enables direct RNA detection in a format amenable to point-of-care infection diagnosis, as well as to a wide range of other diagnostic or research applications.

[1]  Stan J. J. Brouns,et al.  SCOPE: Flexible targeting and stringent CARF activation enables type III CRISPR-Cas diagnostics , 2021, bioRxiv.

[2]  D. Patel,et al.  The Card1 nuclease provides defence during Type III CRISPR immunity , 2021, Nature.

[3]  Michael V. D’Ambrosio,et al.  Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a and mobile phone microscopy , 2020, Cell.

[4]  D. Larremore,et al.  Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening , 2020, Science Advances.

[5]  Matthew P. Taylor,et al.  Intrinsic Signal Amplification by Type-III CRISPR-Cas Systems Provides a Sequence-Specific Viral Diagnostic , 2020, medRxiv.

[6]  Daniel B Larremore,et al.  Rethinking Covid-19 Test Sensitivity - A Strategy for Containment. , 2020, The New England journal of medicine.

[7]  J. Joung,et al.  Detection of SARS-CoV-2 with SHERLOCK One-Pot Testing , 2020, The New England journal of medicine.

[8]  J. Doudna,et al.  Chemistry of Class 1 CRISPR-Cas effectors: Binding, editing, and regulation , 2020, The Journal of Biological Chemistry.

[9]  V. Šikšnys,et al.  Type III-A CRISPR-associated protein Csm6 degrades cyclic hexa-adenylate activator using both CARF and HEPN domains , 2020, Nucleic acids research.

[10]  Eric Song,et al.  Analytical sensitivity and efficiency comparisons of SARS-CoV-2 RT–qPCR primer–probe sets , 2020, Nature Microbiology.

[11]  Ru Huang,et al.  CRISPR/Cas13a Powered Portable Electrochemiluminescence Chip for Ultrasensitive and Specific MiRNA Detection , 2020, Advanced science.

[12]  P. V. Van Caeseele,et al.  Predicting Infectious Severe Acute Respiratory Syndrome Coronavirus 2 From Diagnostic Samples , 2020, Clinical Infectious Diseases.

[13]  Zachary Schiffman,et al.  Predicting infectious SARS-CoV-2 from diagnostic samples , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  N.-G. Kim,et al.  Point-of-care testing for COVID-19 using SHERLOCK diagnostics , 2020, medRxiv.

[15]  Guixia Yu,et al.  CRISPR-Cas12–based detection of SARS-CoV-2 , 2020, Nature Biotechnology.

[16]  Megan L Hochstrasser,et al.  Blueprint for a pop-up SARS-CoV-2 testing lab , 2020, Nature Biotechnology.

[17]  Jonathan Hall,et al.  Activation and self-inactivation mechanisms of the cyclic oligoadenylate-dependent CRISPR ribonuclease Csm6 , 2020, Nature Communications.

[18]  M. F. White,et al.  The dynamic interplay of host and viral enzymes in type III CRISPR-mediated cyclic nucleotide signalling , 2020, bioRxiv.

[19]  Stan J. J. Brouns,et al.  Evolutionary classification of CRISPR–Cas systems: a burst of class 2 and derived variants , 2019, Nature Reviews Microbiology.

[20]  M. F. White,et al.  Structure and mechanism of a Type III CRISPR defence DNA nuclease activated by cyclic oligoadenylate , 2019, Nature Communications.

[21]  Mingxia Feng,et al.  Structure of Csx1-cOA4 complex reveals the basis of RNA decay in Type III-B CRISPR-Cas , 2019, Nature Communications.

[22]  Roger A. Jones,et al.  CRISPR-Cas III-A Csm6 CARF Domain Is a Ring Nuclease Triggering Stepwise cA4 Cleavage with ApA>p Formation Terminating RNase Activity. , 2019, Molecular cell.

[23]  P. J. Kranzusch,et al.  Structure and mechanism of a cyclic trinucleotide-activated bacterial endonuclease mediating bacteriophage immunity , 2019, bioRxiv.

[24]  E. Nogales,et al.  Target preference of Type III-A CRISPR-Cas complexes at the transcription bubble , 2019, Nature Communications.

[25]  M. F. White,et al.  A Type III CRISPR Ancillary Ribonuclease Degrades Its Cyclic Oligoadenylate Activator , 2019, bioRxiv.

[26]  Jennifer A. Doudna,et al.  CRISPR-Cas guides the future of genetic engineering , 2018, Science.

[27]  M. F. White,et al.  Ring nucleases deactivate Type III CRISPR ribonucleases by degrading cyclic oligoadenylate , 2018, Nature.

[28]  James J. Collins,et al.  Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6 , 2018, Science.

[29]  Frank Schwede,et al.  Type III CRISPR–Cas systems produce cyclic oligoadenylate second messengers , 2017, Nature.

[30]  D. Burstein,et al.  RNA Targeting by Functionally Orthogonal Type VI-A CRISPR-Cas Enzymes. , 2017, Molecular cell.

[31]  Aviv Regev,et al.  Nucleic acid detection with CRISPR-Cas13a/C2c2 , 2017, Science.

[32]  Jennifer A. Doudna,et al.  Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection , 2016, Nature.

[33]  M. Jinek,et al.  Structural basis for the endoribonuclease activity of the type III-A CRISPR-associated protein Csm6 , 2016, RNA.

[34]  Yunpeng Li,et al.  CIDRE: an illumination-correction method for optical microscopy , 2015, Nature Methods.

[35]  Olaf Piepenburg,et al.  DNA Detection Using Recombination Proteins , 2006, PLoS biology.

[36]  T. Notomi,et al.  Accelerated reaction by loop-mediated isothermal amplification using loop primers. , 2002, Molecular and cellular probes.

[37]  D. Chitwood,et al.  Cc-by-nc-nd 4.0 International License , 2022 .